Cohance Lifesciences Ltd
COHANCEBSE 543064PharmaceuticalsMkt cap ₹17,272 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹422 Cr
YoY -23.1%QoQ -31.8%
Net profit · Q1 FY27
₹-45.19 Cr
YoY -197.4%QoQ -643.8%
Net margin · Q1 FY27
-10.7%
-19.1 pts vs Q1 FY26
Net profit · FY26
₹150 Cr
YoY -43.3%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 422 | 619 | 545 | 556 | 549 | -23.1% |
| Other income | 12.25 | -1.84 | 6.16 | 15.60 | 14.17 | -13.5% |
| Total income | 435 | 617 | 551 | 571 | 563 | -22.9% |
| Profit before tax | 0.00 | 19.91 | 40.60 | 83.77 | 62.76 | -100.0% |
| Tax | 2.32 | 11.60 | 11.58 | 17.38 | 16.36 | -85.8% |
| Net profit | -45.19 | 8.31 | 29.02 | 66.39 | 46.40 | -197.4% |
| Net margin | -10.7% | 1.3% | 5.3% | 11.9% | 8.4% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 2,269 | 1,198 | 1,051 | 1,340 | 1,320 | +89.4% |
| Other income | 34.09 | 58.56 | 61.91 | 46.36 | 92.38 | -41.8% |
| Total income | 2,303 | 1,256 | 1,113 | 1,387 | 1,413 | +83.3% |
| Profit before tax | 207 | 344 | 406 | 560 | 626 | -39.8% |
| Tax | 56.92 | 79.15 | 105 | 148 | 214 | -28.1% |
| Net profit | 150 | 265 | 300 | 411 | 454 | -43.3% |
| Net margin | 6.6% | 22.1% | 28.6% | 30.7% | 34.4% |
BIC's take
We haven't covered Cohance Lifesciences Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:05 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.